Dozens of biotech companies hope to use stem cell technologies to make products that turn a profit, but very few have. Cellular Dynamics International, which sells cardiomyocytes—heart muscle cells—derived from induced pluripotent stem cells, is an exception.
No takes yet. Share an insight, caveat, or question.
Gretchen Vogel (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: